Skip to main content

Table 1 Summary of the cases of heterotopic pancreas adenocarcinoma in the duodenum found in the literature

From: Adenocarcinoma arising from a heterotopic pancreas in the first portion of the duodenum: a case report

Case

Year

Author

Age

Sex

Location

Size (mm)

Biopsy

Preoperative tumor-specific antigen

Diagnostic approach

Lymphadenectomy

Lymph node metastasis

Heinrich classification

Chemotherapy

PFS (months)

1

2007

Tison

72

M

2nd

N.D

Negative

N.D

Ope (PD)

Performed (N.D)

+

N.D

N.D

N.D

2

2007

Kawakami

65

F

2nd

12

Not performed

WNL

Ope (SSPPD)

The regional lymph nodes

N.D

N.D

N.D

19

3

2008

Rosok

59

F

Proximal

50

Negative

N.D

Ope (lap-D)

Not performed

N.D

Not performed

36

4

2010

Inoue

75

M

2nd

30

Negative

WNL

Ope (PPPD)

The regional lymph nodes

+

III

Not performed

72

5

2010

Bini

56

M

1st

N.D

Adenocarcinoma

WNL

EUS-FNA → Ope (PD)

The regional lymph nodes

I

Performed (N.D)

N.D

6

2011

Stock

79

F

4th

30

Negative

Chromogranin-A, 53 mg/mL

Ope (D)

The regional lymph nodes

+

I

Performed (N.D)

N.D

7

2012

Kinoshita

62

F

1st

34

Negative

CEA, 8.1 U/mL

Ope (PD)

The regional lymph nodes

I

Not performed

12

        

CA19-9, 66.9 U/mL

      

8

2013

Ginori

86

F

1st

30

Not performed

N.D

Ope (subTG)

The regional lymph nodes

I

Not performed

N.D

9

2013

Alireza

58

M

1st

27

Not performed

N.D

Ope (D)

Not performed

N.D

Performed (XELOX)

18

10

2014

Endo

75

M

2nd

22

Adenocarcinoma

CEA, 55.4 U/mL

EUA-FNA → Ope (SSPPD)

N.D

N.D

I

Not performed

60

        

CA19-9, 54.8 U/mL

      

11

2015

Fukino

62

M

4th

15

Negative

CA19-9, 500 U/mL

Ope (D)

N.D

N.D

IV

Performed (SP)

N.D

        

DUPAN-2, 226 U/mL

      

12

2019

Kaneko

81

M

1st

30

Negative

WNL

Ope (DG)

The regional lymph nodes

+

I

Not performed

18

13

2020

Our case

77

M

1st

55

Negative

CA19-9, 1130 U/mL

Ope (SSPPD)

The regional lymph nodes

+

I

Performed (TS1)

9

        

DUPAN-2, 5287 U/mL

      
  1. CEA carcinoembryonic antigen, CA carbohydrate antigen, DUPAN duke pancreatic monoclonal antigen, EUS-FNA endoscopic ultrasonography-guided fine-needle aspiration, N.D not dated, PFS progression-free survival, D (partial) duodenectomy, DG distal gastrectomy, TG total gastrectomy, PD pancreatoduodenectomy, PPPD pylorus-preserving pancreatoduodenectomy, SSPPD subtotal stomach-preserving pancreatoduodenectomy, SMT submucosal tumors, TS1 tegafur-gimeracil-dihydropyrimidine dehydrogenase, SP TS1+cisplatin, XELOX capecitabine+oxaliplatin, WNL within normal limits